placebo, in previous randomised controlled induction studies. 3 However, relapse of symptoms after budesonide discontinuation is common (60%-80%). 4, 5 Maintenance therapy with low-dose budesonide is usually considered if a patient relapses after induction therapy. 6 In three randomised controlled trials, budesonide (4.5-6 mg/d) was superior to placebo as maintenance therapy for 6-12 months of treatment; however, relapse rates were high after budesonide discontinuation and many patients became budesonide dependent. [7] [8] [9] In addition, some patients are refractory to corticosteroids and others do not tolerate long-term treatment with these medications. As a result, immunosuppressants such as methotrexate or azathioprine have been used, [10] [11] [12] [13] although data on outcomes of these corticosteroid-sparing treatment options remain limited.
Thiopurines are the best studied corticosteroid-sparing option for active microscopic colitis. In 2001, a small case series consisting of nine patients with corticosteroid-dependent or -refractory microscopic colitis reported an 89% response rate and a corticosteroidsparing effect with thiopurines. 11 Subsequently, a smaller case series reported a 50% response rate. 12 More recently, a larger case series involving three European centres reported their experience with thiopurines in 46 patients with active microscopic colitis and found an overall response rate of 41%. 14 There are even less data on the use of methotrexate in active microscopic colitis, with conflicting results. In a retrospective study, methotrexate was successful in 16 of 19 patients. 13 However, a recent open label case series reported that none of nine patients achieved a response with methotrexate. 15 Anti-tumour necrosis factor (anti-TNF) therapies such as infliximab and adalimumab have been also used rarely in patients with microscopic colitis, usually in an attempt to avoid colectomy. Two small case series and two case reports have shown promising outcomes with anti-TNF therapy. [16] [17] [18] [19] Given the limitations of the existing literature on the efficacy and safety of these medications in microscopic colitis, we sought to describe our institution's experience using these corticosteroid-sparing options in active microscopic colitis. The Institutional Review Board approved the study.
| MATERIALS AND METHODS
3 | RESULTS
| Patient characteristics
The study cohort consisted of 73 patients (61 females, 84%). were on a concomitant budesonide taper for a median duration of 3 months (range, 1.5-7). Of these 37 patients, 15 patients (41%)
were successfully tapered completely off budesonide, 10 patients (27%) were weaned to lower doses, while 12 patients (32%) continued on the same dose of budesonide. Seventeen patients (35%) experienced adverse events that resulted in treatment cessationamong these, five had achieved a complete response (Table 2 ). There were no differences in outcomes between patients with lymphocytic vs collagenous colitis (P=1.0).
Of the 21 patients who achieved complete response, 17 continued maintenance therapy (defined as 3 months or greater of therapy), for a median of 14 (9-24) months, with one patient continuing for 108 months. Four of these patients stopped treatment due to adverse events occurring after a mean of 11AE2 months. Only one relapsed (after 30 months) while on maintenance therapy.
Three patients (mean age of 49AE6. Five with rheumatoid arthritis.
T A B L E 2 Treatment-limiting adverse events associated with thiopurine use in patients with active microscopic colitis

Number (%), N=49
Nausea/emesis, n (%) 5 (10)
Abnormal liver enzymes, n (%) 2 (4)
Abdominal pain, n (%) 3
Fever/chills, n (%) 2 (4)
Recurrent fungal infections, n (%) 1
Intractable pruritus, n (%) 1 (2)
| Calcineurin inhibitor treatment group
Calcineurin inhibitors were used in two patients (3%) (one on tacrolimus, one on ciclosporin) for a median of 4 months (range, 1.5-15).
One patient treated with tacrolimus, who was not on concomitant budesonide therapy, had complete response. There were no adverse effects reported in this study group.
| Anti-TNF treatment group
Anti 
| DISCUSSION
In this large retrospective case series of patients with budesonide refractory, budesonide-dependent or budesonide-intolerant microscopic colitis, treatment with thiopurines, methotrexate, or anti-TNFs resulted in clinical response in the majority. Notably, there were more adverse effects in the thiopurine group.
The clinical outcomes in patients treated with thiopurines are comparable to those from previous studies. In a recent European case series of 46 patients, the overall response rate was 41%, similar to our complete response rate of 43%. 14 An earlier case series of nine patients reported a slightly higher complete response rate of 56%. 11 In addition, almost half of our patients on concomitant budesonide were successfully tapered, representing a budesonide-sparing effect. However, 59% of our patients
were not tapered completely off budesonide, which is a major goal of immune modulator therapy. Moreover, once complete response was achieved, only one patient relapsed while on maintenance therapy. However, adverse events that resulted in therapy cessation were common (35%), including four patients who had achieved complete response and continued on maintenance therapy. Our rate of adverse events rate was lower than that in the European case series, which reported a rate of 67%. 14 Interestingly, two of three patients responded well to mercaptopurine after failing azathioprine therapy. The trial of mercaptopurine after azathioprine failure has been previously recommended for inflammatory bowel disease patients, 21 and is supported for use in microscopic colitis by the previous European case series which reported a 48% response rate with mercaptopurine in 13 azathioprine-intolerant patients. 14 There was a high complete response rate (58%) among patients treated with methotrexate and this treatment was generally well tolerated, with only one patient experiencing an adverse event resulting in treatment cessation. In another case series of 10 patients with collagenous colitis, oral low-dose methotrexate appeared safe and effective. 22 These outcomes are in contrast to a recent prospective study of nine patients with budesoniderefractory collagenous colitis treated with methotrexate 25 mg once weekly. 15 Four patients (44%) discontinued treatment due to adverse events and none of the remaining five patients responded at week 12 of treatment. Only three of these patients (33%) were on concomitant budesonide therapy, compared to 75% of our cohort, possibly explaining some of the difference between the outcomes. Moreover, half the patients had an additional indication for methotrexate therapy, possibly leading to earlier use of methotrexate than would usually be expected in clinical practice in patients with microscopic colitis alone. Given our findings, methotrexate may be useful in the treatment of budesoniderefractory microscopic colitis. It is noteworthy that patients treated with methotrexate received a dose that has been used successfully for treating Crohn's disease. 23 In contrast, a number of the patients treated with a thiopurine received a suboptimal dose of less than 2 mg/kg of azathioprine or less than 1 mg/kg of mercaptopurine. Perhaps the lower dosing of the thiopurines was a factor in the lower success rate as compared to treatment with methotrexate.
To our knowledge, there have been no previous descriptions of calcineurin inhibitor use in patients with microscopic colitis. In our study, there were only two patients treated with calcineurin inhibitors (one on tacrolimus, one on ciclosporin) with one patient achieving complete response. Both patients tolerated treatment well. Given the low sample size, no strong conclusion can be made with regard to calcineurin inhibitor therapy in active microscopic colitis.
With regard to anti-TNF-therapies, in a previous case series of 4 patients, 16 all responded to infliximab with at least a 60% decrease in bowel movements. However, three of these patients had to switch to adalimumab due to adverse events. In three of these cases, long-term clinical remission (>1 year) was achieved. In another study, three patients had clinical response to adalimumab; however, one patient stopped due to adverse effects. 17 In our case series, almost half of patients treated with anti-TNF therapy achieved complete response, however, the short treatment duration did not allow for assessment of effectiveness and safety of anti-TNF therapy as maintenance therapy. Nevertheless, our results support future research investigating the role of anti-TNF therapy in refractory microscopic colitis.
The strengths of this study include its relatively large sample size from a single centre institution. Furthermore, the vast majority of our patients underwent coeliac disease testing (Table 1 ) and a trial of bile-acid binders helping to ensure that our cohort's diarrhoea was attributable to active microscopic colitis. The limitations of our study include the retrospective nature of the study, and the concern that the duration of follow-up on therapy may not have been long enough to fully capture outcomes, including patients who subsequently relapsed while on therapy after their last follow-up at our institution. Furthermore, the retrospective design did not allow us to ascertain an accurate time to induction of response.
In conclusion, thiopurines appear to be effective in active microscopic colitis. A budesonide-sparing effect was evident and when used as maintenance therapy, relapse was uncommon. However, tolerability is a concern given the high rate of treatment-ending adverse events in our cohort. Our study also suggests that a trial of mercaptopurine may be worthwhile should a patient fail to respond to azathioprine. Methotrexate had a high response rate and was well tolerated, suggesting it may have a role in the treatment of active microscopic colitis. No conclusion can be made about calcineurin inhibitor therapy given the low patient numbers in this cohort. Anti-
TNF therapy also appears effective in treating refractory microscopic colitis, however, safety and effectiveness of maintenance therapy was unable to be ascertained. Larger controlled studies are required to confirm efficacy and safety of these medications in microscopic colitis. All authors approved final version to be published, including the authorship list.
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